FDA panel to review GlaxoSmithKline multiple myeloma drug next month

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jun 25, 2020 at 10:42: AM
via The drug, belantamab mafodotin, could become the first approved therapy for multiple myeloma that targets the cell-surface antigen BCMA. The FDA accepted the application for the drug in January.

article source
 

<



Similar threads

cafead
FDA panel to review psychedelic drug MDMA for first time
Replies
0
Views
37
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA offers former biotech unicorn Intarcia a chance for a panel review
Replies
0
Views
104
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
As GSK gears up for high-stakes daprodustat panel review, FDA flags some safety concerns
Replies
0
Views
194
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA panel to review once-rejected Acadia drug for psychosis
Replies
0
Views
145
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Merck’s Covid-19 Pill Set for Review by FDA Advisory Panel
Replies
0
Views
143
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote